Prokinetics for functional dyspepsia

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 11, 2017, Pages

  Pittayanon, Rapat ^a   Yuan, Yuhong ^a   Bollegala, Natasha P ^b   Khanna, Reena ^c   Leontiadis, Grigorios I ^a   Moayyedi, Paul ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACOTIAMIDE; ALEMCINAL; ALOSETRON; CISAPRIDE; DOMPERIDONE; ERYTHROMYCIN; ITOPRIDE; METOCLOPRAMIDE; MOSAPRIDE; PLACEBO; PROKINETIC AGENT; TANDOSPIRONE; TEGASEROD;

ARTICLE; CLINICAL PROTOCOL; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISTRESS SYNDROME; DRUG EFFICACY; DYSPEPSIA; EPIGASTRIC PAIN; HUMAN; META ANALYSIS; OUTCOME ASSESSMENT; POSTPRANDIAL DISTRESS SYNDROME; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW;

EID: 85032738980     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009431.pub2     Document Type: Article

References (20)

1. Deeks JJ, Higgins JPT, Deeks JJ, Altman DG, on behalf of the Cochrane Statistical Methods Group, editors. Chapter 9.4: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
2. Ford AC, Marwaha A, Lim A, Moayyedi P. What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2010;8:830-7.
3. Ford AC, Marwaha A, Sood R, Moayyedi P. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. Gut 2015;64(7):1049-57.
4. GRADE Working Group, McMaster University. GRADE Working Group, McMaster University. GRADEpro GDT. Version (accessed prior to April 22, 2017). Hamilton (ON): GRADE Working Group, McMaster University, 2015.
5. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
6. Higgins JPT, Deeks JJ, Altman DG, on behalf of the Cochrane Statistical Methods Group, editors. Chapter 16.1.3.2: Imputing standard deviations for changes from baseline. In: Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
7. Lacy BE, Talley NJ, Locke GR 3rd, Bouras EP, DiBaise JK, El-Serag HB, et al. Review article: current treatment options and management of functional dyspepsia. Alimentary Pharmacology & Therapeutics 2012;36(1):3-15.
8. Lacy BE, Weiser KT, Kennedy AT, Crowell MD, Talley NJ. Functional dyspepsia: the economic impact to patients. Alimentary Pharmacology & Therapeutics 2013;38:170-7.
9. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22(4):719-48.
10. Moayyedi P, Mason J. Clinical and economic consequences of dyspepsia in the community. Gut 2002;50 (suppl 4):10-2.
11. Moayyedi P, Soo S, Deeks JJ, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database of Systematic Reviews 2011, Issue 12. [DOI: 10.1002/14651858.CD001960.pub4]
12. Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. Corrigendum: ACG and CAG clinical guideline: management of dyspepsia. American Journal of Gastroenterology 2017;112:1484. [DOI: 10.1038/ajg.2017.238]
13. Stanghellini V, Chan FK, Hasler WL, Malagelada JR, Suzuki H, Tack J, et al. Gastroduodenal disorders. Gastroenterology 2016;150:1380-92.
14. Tack J, Talley MJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology 2006;130:1466-79.
15. Talley NJ, Colin-Jones DG, Koch KL, Koch M, Nyren O, Stanghellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterology International 1991;4:145-60.
16. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999;45 (Suppl 2):II37-42. [MEDLINE: 10457043]
17. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-80.
18. van Zanten SV, Wahlqvist P, Talley NJ, Halling K, Vakil N, Lauritsen K, et al. Randomised clinical trial: the burden of illness of uninvestigated dyspepsia before and after treatment with esomeprazole-results from the STARS II study. Alimentary Pharmacology & Therapeutics 2011;34(7):714-23.
19. Vanheel H, Farré R. Changes in gastrointestinal tract function and structure in functional dyspepsia. Nature Reviews. Gastroenterology & Hepatology 2013;10:142-9.
20. Bollegala NP, Khanna R, Moayyedi P, Leontiadis GI. Prokinetics for functional dyspepsia. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD009431]